Acta Med. 2017, 60: 152-156
https://doi.org/10.14712/18059694.2018.11
Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation
Filip Gabaleca
, Martin Šimkoviča, Alžběta Zavřelováa, Petra Kašparováb, Paula Morávkovác, Marcela Kopáčovác, Václav Masopustd, Pavel Žáka, Jan Čápa, Jakub Radochaa
, Martin Šimkoviča, Alžběta Zavřelováa, Petra Kašparováb, Paula Morávkovác, Marcela Kopáčovác, Václav Masopustd, Pavel Žáka, Jan Čápa, Jakub Radochaa
a4th Department of Internal Medicine – Haematology, University Hospital Hradec Králové, Czech Republic and Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
bFingerland’s Department of Pathology, University Hospital Hradec Králové, Czech Republic and Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
c2nd Department of Internal Medicine – Gastroenterology, University Hospital Hradec Králové, Czech Republic and Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
dNeurosurgery Clinic, Central Military Hospital Prague, Prague, Czech Republic
Received October 24, 2017
Accepted December 20, 2017
References
1. S, Kudo N, Kaneda S, et al. Treatment of patients with hypothalamic- pituitary lesions as adult-onset Langerhans cell histiocytosis. International Journal of Hematology 2011; 94(6): 556–560.
<https://doi.org/10.1007/s12185-011-0955-z>
2. S, Emile JF, Barkaoui MA, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2016; 34(25): 3023–3030.
<https://doi.org/10.1200/JCO.2015.65.9508>
<PubMed>
3. S, Wang YY, Wong R. Pituitary stalk lesions: systematic review and clinical guidance. Clinical Endocrinology 2016; 85(4): 507–521.
<https://doi.org/10.1111/cen.13058>
4. S, Popovic V. Diagnosis of endocrine disease: Expanding the cause of hypopituitarism. European Journal of Endocrinology 2017; 176(6): R269-R282.
<https://doi.org/10.1530/EJE-16-1065>
5. M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatric Blood & Cancer 2009; 52(1): 97–101.
<https://doi.org/10.1002/pbc.21782>
6. P, Alexandraki KI, Chrousos GP, Grossman AB, Kaltsas GA. Endocrine manifestations in Langerhans cell histiocytosis. Trends in Endocrinology and Metabolism: TEM 2007; 18(6): 252–257.
<https://doi.org/10.1016/j.tem.2007.06.003>
7. J, Cohen-Aubart F, Rollins BJ, et al. Histiocytoses: Emerging Neoplasia behind Inflammation. The Lancet Oncology 2017; 18(2): e113-e125.
<https://doi.org/10.1016/S1470-2045(17)30031-1>
8. Z, Szturz P, Vanicek J, et al. Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. Acta Oncologica 2013; 52(5): 994–1001.
<https://doi.org/10.3109/0284186X.2012.716164>
9. U, Prasad M, Chaurasia OP. A rare case of langerhans cell histiocytosis of the gastrointestinal tract. World Journal of Gastroenterology 2012; 18(12): 1410–1413.
<https://doi.org/10.3748/wjg.v18.i12.1410>
<PubMed>
10. C, Alexander J, Gould A, Talbot R, Snook JA. Langerhan’s cell histiocytosis complicating small bowel Crohn’s disease. Gut 1996; 38(2): 296–298.
<https://doi.org/10.1136/gut.38.2.296>
<PubMed>
11. V, Donadieu J, Piguet C, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplantation 2003; 31(12): 1097–1103.
<https://doi.org/10.1038/sj.bmt.1704065>
12. M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplantation 2005; 36(3): 215–225.
<https://doi.org/10.1038/sj.bmt.1705015>
13. N, Rao K, Goulden N, Webb D, Amrolia P, Veys P. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplantation 2008; 42(Suppl 2): S47–50.
<https://doi.org/10.1038/bmt.2008.283>
14. W, Desai SR, Gibbs JS, Mufti G. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans’ cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplantation 2006; 37(7): 713–715.
<https://doi.org/10.1038/sj.bmt.1705300>
15. B, Ribera JM, Batlle M, Feliu E. [Sustained remission in an adult patient with Langerhans cell histiocytosis following T-cell depleted allogenic cell transplantation]. Medicina Clinica 2006; 127(18): 716.
<https://doi.org/10.1157/13095100>
